美股异动 1期SENTI-202试验数据积极 Senti Biosciences(SNTI.US)开盘涨超7%

Core Viewpoint - Senti Biosciences (SNTI.US) reported promising data from its Phase 1 trial of SENTI-202 in R/R AML, showing a total overall response rate of 50% and a complete response/hematologic response rate of 42%, with most patients achieving minimal residual disease negativity [1] Group 1 - Senti Biosciences opened with a gain of over 7%, reaching a price of $2.54 [1] - The updated data from the Phase 1 trial indicates a significant efficacy in treating R/R AML [1] - The company received Regenerative Medicine Advanced Therapy (RMAT) designation to advance to pivotal studies [1]